Teams Enable groups of users to work together to streamline your digital publishing
Xie Z, Konopleva M, Zhao S, Cortes J, Andreeff M
4 Pharmacokinetic properties A full understanding of its behavior in biological systems, essential for further caudatin development as a clinical agent, can only be achieved since the pharmacokinetic (PK) profile determines absorption, distribution, metabolism, and elimination (ADME), and parameters that control both safety and efficacy ( Quantitative characterization of the caudatin PK profile has been primarily derived from studies in rats, and particularly those that have successfully quantified using sensitive UPLC-MS/MS technology ( The pharmacokinetic profile of caudatin undergoes substantial modification in pathological states, particularly HCC
J Diabetes Investig 7(1Suppl 1):7679 Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT et al (2018) Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo
